Xiangxue Pharmaceutical Co.,Ltd.
Shenzhen Stock ExchangeTotal Valuation
Xiangxue Pharmaceutical Co.,Ltd. carries a market capitalization of 6.32B, placing it among publicly traded companies globally. Its enterprise value stands at 8.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.32B |
| Enterprise Value | 8.15B |
Share Statistics
Xiangxue Pharmaceutical Co.,Ltd. currently has 661.28M shares outstanding.
| Shares Outstanding | 661.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.55, and the price-to-book ratio stands at -3.99.
| PE Ratio | N/A |
| PS Ratio | 3.55 |
| PB Ratio | -3.99 |
| P/TBV Ratio | -215.33 |
| P/FCF Ratio | 292.74 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Xiangxue Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 63.41 and an EV/FCF ratio of 29.08. The EV/Sales ratio of 5.16 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 63.41 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.16 |
| EV / EBITDA | 63.41 |
| EV / EBIT | 63.41 |
| EV / FCF | 29.08 |
Financial Position
Xiangxue Pharmaceutical Co.,Ltd. maintains a current ratio of 0.27, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 182.74, indicating elevated leverage, while an interest coverage ratio of -0.95 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.27 |
| Quick Ratio | 0.02 |
| Debt / Equity | 182.74 |
| Debt / EBITDA | -9.16 |
| Interest Coverage | -0.95 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -12.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.40 |
Taxes
| Income Tax | 14.72M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Xiangxue Pharmaceutical Co.,Ltd.'s stock has gained approximately 15.94203% over the past 52 weeks. The 50-day moving average sits at 9.87, while the 200-day moving average is 9.76.
| Beta (5Y) | N/A |
| 52-Week Price Change | 15.94203% |
| 50-Day Moving Average | 9.87 |
| 200-Day Moving Average | 9.76 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Xiangxue Pharmaceutical Co.,Ltd. generated 1.58B in revenue and converted that into -957.21M in net income, yielding earnings per share of -1.42. EBITDA reached -243.71M, while operating income came in at -243.71M.
| Revenue | 1.58B |
| Gross Profit | 323.79M |
| Operating Income | -243.71M |
| Pretax Income | -943.29M |
| Net Income | -957.21M |
| EBITDA | -243.71M |
| EBIT | -243.71M |
| Earnings Per Share (EPS) | -1.42 |
Balance Sheet
Xiangxue Pharmaceutical Co.,Ltd. holds 96.22M in cash and equivalents against 2.23B in total debt, resulting in a net debt position of 1.39B. Total book value stands at -1.41B, with working capital of -4.35B providing operational flexibility.
| Cash & Cash Equivalents | 96.22M |
| Total Debt | 2.23B |
| Net Debt | 1.39B |
| Equity (Book Value) | -1.41B |
| Book Value Per Share | -2.09 |
| Working Capital | -4.35B |
Cash Flow
After subtracting -19.18M in capital expenditures, free cash flow totaled -19.18M - equivalent to -0.03 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -19.18M |
| Free Cash Flow | -19.18M |
| FCF Per Share | -0.03 |
Margins
Xiangxue Pharmaceutical Co.,Ltd. operates with a gross margin of 20.49, reflecting its pricing power and cost economics. The operating margin of -15.42 and net profit margin of -60.58 provide insight into operational efficiency.
| Gross Margin | 20.49 |
| Operating Margin | -15.42 |
| Pretax Margin | -59.70 |
| Profit Margin | -60.58 |
| EBITDA Margin | -15.42 |
Dividends & Yields
The company's payout ratio of -0.07 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -0.07 |
| Shareholder Yield | 0.16 |
| FCF Yield | 0.34 |
Stock Splits
Xiangxue Pharmaceutical Co.,Ltd.'s most recent stock split took place on June 18, 2015 with a 125:151 split ratio.
| Last Split Date | 6/18/2015 |
| Split Ratio | 125:151 |
Scores
Xiangxue Pharmaceutical Co.,Ltd. posts an Altman Z-Score of -0.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.65 |